Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.
about
Beyond BRAF: where next for melanoma therapy?Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateAxl as a mediator of cellular growth and survivalActivity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
P2860
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@ast
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@en
type
label
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@ast
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@en
prefLabel
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@ast
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@en
P2093
P2860
P1433
P1476
Amuvatinib has cytotoxic effec ...... but not BRAF-mutant melanoma.
@en
P2093
Geoffrey T Gibney
Inna V Fedorenko
John M Koomen
P2860
P304
P356
10.1097/CMR.0000000000000103
P407
P577
2014-10-01T00:00:00Z